Email Alert RSS
Volume 11 Issue 5
Sep.  2020
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2020  >  11(5): 559-570
Chinese Committee on Antimicrobial Susceptibility Testing, European Committee on Antimicrobial Susceptibility Testing, European Society of Clinical Microbiology and Infectious Diseases, Expert Committee on Infectious Diseases, China Medical Education Association, YANG Qi-wen, MA Xiao-ling, HU Fu-pin, ZHANG Jing, SUN Tong-wen, CHEN Bai-yi, XU Ying-chun, LIU You-ning. Expert Consensus on Polymyxin Antimicrobial Susceptibility Testing and Clinical Interpretation[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 559-570. doi: 10.3969/j.issn.1674-9081.2020.05.011
Citation: Chinese Committee on Antimicrobial Susceptibility Testing, European Committee on Antimicrobial Susceptibility Testing, European Society of Clinical Microbiology and Infectious Diseases, Expert Committee on Infectious Diseases, China Medical Education Association, YANG Qi-wen, MA Xiao-ling, HU Fu-pin, ZHANG Jing, SUN Tong-wen, CHEN Bai-yi, XU Ying-chun, LIU You-ning. Expert Consensus on Polymyxin Antimicrobial Susceptibility Testing and Clinical Interpretation[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 559-570. doi: 10.3969/j.issn.1674-9081.2020.05.011
shu

Expert Consensus on Polymyxin Antimicrobial Susceptibility Testing and Clinical Interpretation

doi: 10.3969/j.issn.1674-9081.2020.05.011
  • 1.

    Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 2.

    Department of Laboratory Medicine, The First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China

  • 3.

    Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China

  • 4.

    General ICU, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

  • 5.

    Department of Infectious Diseases, The First Affiliated Hospital of China Medical University, Shenyang 110001, China

  • 6.

    Department of Respiratory Medicine, The First Medical Center of PLA General Hospital, Beijing 100853, China

Funds:

National Key Research & Development Program 2018YFC1200100

National Key Research & Development Program 2018YFC1200105

Major Research and Development Project of Innovative Drugs, Ministry of Science and Technology of China 2017ZX09304005

More Information
  • Corresponding author: XU Ying-chun Tel: 86-10-69159766, E-mail: xycpumch@139.com; LIU You-ning  Tel: 86-10-66939114, E-mail: liuyn301@126.com
  • Received Date: 2020-08-26
  • Publish Date: 2020-09-30
    Abstract
  • Polymyxin was an important antimicrobial agent against resistant Gram-negative bacilli. In 2020, the American Clinical and Laboratory Standards Institute changed the clinical breakpoints of polymyxin, eliminating the "susceptible" interpretive category, and only reporting intermediate (I≤2 mg/L) and resistant(R≥4 mg/L) ones. However, the European Committee on Antimicrobial Susceptibility Testing recommended the use of susceptible (S≤2 mg/L), resistant (R > 2 mg/L) as the clinical breakpoints. The international disunity of clinical breakpoints of polymyxin brings great trouble to the domestic clinical staffs. Therefore, how to accurately carry out the susceptibility test of polymyxin and standardize the interpretation of its report is an urgent problem to be solved in the field of antibacterial drug application and anti-infection in China. To this end, we organized experts in related fields to normalize and interpret the susceptibility test of polymyxin and its results, and put forward corresponding suggestions of experts for reference.
    • FullText(HTML)
  • loading
    • References(48)
  • [1] Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing [M]. 30th Edition. USA: Wayne, 2020:38-48.
    [2] The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0, 2020[EB/OL].http://www.eucast.org.
    [3] Pogue JM, Jones RN, Bradley JS, et al. Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommenda-tions from the United States Committee on Antimicrobial Susceptibility Testing (USCAST) [J]. Antimicrob Agents Chemother, 2020, 64:e01495-19.
    [4] 李焕芹, 牛敏, 刘淑敏, 等. CRE对多黏菌素B的敏感性及两种检测方法的差异[J].中国感染控制杂志, 2019, 18:1059-1063. http://www.cnki.com.cn/Article/CJFDTotal-GRKZ201911012.htm
    [5] Chew KL, La MV, Lin RTP, et al. Colistin and Polymyxin B Susceptibility Testing for Carbapenem-Resistant and mcr-Positive Enterobacteriaceae: Comparison of Sensititre, MicroScan, Vitek 2, and Etest with Broth Microdilution [J]. J Clin Microbiol, 2017, 55:2609-2616. doi:  10.1128/JCM.00268-17
    [6] Pfennigwerth N, Kaminski A, Korte-Berwanger M, et al. Evaluation of six commercial products for colistin suscepti-bility testing in Enterobacterales [J]. Clin Microbiol Infect, 2019, 25:1385-1389. doi:  10.1016/j.cmi.2019.03.017
    [7] Dafopoulou K, Zarkotou O, Dimitroulia E, et al. Compara-tive Evaluation of Colistin Susceptibility Testing Methods among Carbapenem-Nonsusceptible Klebsiella pneumoniae and Acinetobacter baumannii Clinical Isolates [J]. Antimicrob Agents Chemother, 2015, 59:4625-4630. doi:  10.1128/AAC.00868-15
    [8] van der Heijden IM, Levin AS, de Pedri EH, et al. Compari-son of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P.aeruginosa to polymy-xins [J]. Ann Clin Microbiol Antimicrob, 2007, 6:8. doi:  10.1186/1476-0711-6-8
    [9] Singhal L, Sharma M, Verma S, et al. Comparative Evaluation of Broth Microdilution with Polystyrene and Glass-Coated Plates, Agar Dilution, E-Test, Vitek, and Disk Diffusion for Susceptibility Testing of Colistin and Polymyxin B on Carbapenem-Resistant Clinical Isolates of Acinetobacter baumannii [J]. Microb Drug Resist, 2018, 24:1082-1088. doi:  10.1089/mdr.2017.0251
    [10] Vourli S, Dafopoulou K, Vrioni G, et al. Evaluation of two automated systems for colistin susceptibility testing of carbapenem-resistant Acinetobacter baumannii clinical isolates[J]. J Antimicrob Chemother, 2017, 72:2528-2530. doi:  10.1093/jac/dkx186
    [11] Jayol A, Nordmann P, Andre C, et al. Evaluation of three broth microdilution systems to determine colistin susceptibility of Gram-negative bacilli [J]. J Antimicrob Chemother, 2018, 73: 1272-1278. doi:  10.1093/jac/dky012
    [12] Humphries RM, Green DA, Schuetz AN, et al. Multicenter Evaluation of Colistin Broth Disk Elution and Colistin Agar Test: a Report from the Clinical and Laboratory Standards Institute [J]. J Clin Microbiol, 2019, 57:e01269-19. http://www.researchgate.net/publication/335751928_Multi-center_evaluation_of_colistin_broth_disk_elution_and_colistin_agar_test_a_report_from_the_Clinical_and_Laboratory_Standards_Institute
    [13] CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 29th ed. CLSI supplement M100[S]. Pennsylvania: Clinical and Laboratory Standards Institute, 2019.
    [14] U.S. Food & Drug Administration. Antibacterial Suscepti-bility Test Interpretive Criteria[EB/OL].https://www.fda.gov/drugs/development-resources/antibacterial-susceptibility-test-interpretive-criteria.
    [15] European Committee on Antimicrobial Susceptibility Testing. The EUCAST Subcommittee on MIC distributions and ECOFFs[EB/OL]. https://mic.eucast.org/Eucast2/SearchController/search.jsp?action=performSearch&BeginIndex=0&Micdif=mic&NumberIndex=50&Antib=837&Specium=-1.
    [16] Cheah SE, Wang J, Nguyen VT, et al. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection [J]. J Antimicrob Chemother, 2015, 70:3291-3197. http://jac.oxfordjournals.org/content/70/12/3291
    [17] Landersdorfer CB, Wang J, Wirth V, et al. Pharmaco-kinetics/pharmacodynamics of systemically administered polymy-xin B against Klebsiella pneumoniae in mouse thigh and lung infection models [J]. J Antimicrob Chemother, 2017, 73:462-468. http://europepmc.org/abstract/MED/29149294
    [18] Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP) [J]. Pharmacotherapy, 2019, 39:10-39. doi:  10.1002/phar.2209
    [19] European Medicines Agency Completes Review of Polymy-xin-based Medicines: RecommendationsIssued for Safe Use in Patients with Serious Infections Resistant to Standard Antibiotics[EB/OL].https://www.ema.europa.eu/en/news/european-medicines-agency-completes-review-polymyxin-based-medicines.
    [20] FDA Approved Drug Products. Label and Approval History for Coly-Mycin M, NDA 050108[EB/OL].https://www.access-data.fda.gov/drugsatfda_docs/label/2017/050108s033lbl.pdf.
    [21] Nation RL, Garonzik SM, Thamlikitkul V, et al. Dosing guidance for intravenous colistin in critically ill patients[J]. Clin Infect Dis, 2017, 64: 565-571. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=0d5bee86de1d1dbe12e95290957e1f43
    [22] Rattanaumpawan P, Lorsutthitham J, Ungprasert P, et al. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria[J]. J Antimicrob Chemother, 2010;65:2645-2649. doi:  10.1093/jac/dkq360
    [23] Jitaree K, Sathirakul K, Houngsaitong J, et al. Pharmacokinetic/Pharmacodynamic (PK/PD) Simulation for Dosage Optimization of Colistin Against Carbapenem-Resistant Klebsiella pneumoniae and Carbapenem-Resistant Escherichia coli[J]. Antibiotics (Basel), 2019, 8:125. doi:  10.3390/antibiotics8030125
    [24] Avedissian S, Miglis C, Kubin CJ, et al. Polymyxin B Pharmacokinetics in Adult Cystic Fibrosis Patients [J]. Pharmacotherapy, 2018, 38:730-738. doi:  10.1002/phar.2129
    [25] Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society [J]. Clin Infect Dis, 2016, 63:e61-e111. doi:  10.1093/cid/ciw353
    [26] Miglis C, Rhodes NJ, Avedissian S, et al. Population Pharmacokinetics of Polymyxin B in Acutely Ⅲ Adult Patients [J]. Antimicrob Agents Chemother, 2018, 62:e01475-17. http://www.ncbi.nlm.nih.gov/pubmed/29311071
    [27] 中国研究型医院学会危重医学专业委员会, 中国研究型医院学会感染性疾病循证与转化专业委员会.多黏菌素临床应用中国专家共识[J].中华危重病急救医学, 2019, 28:1218-1222. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgwzbjjyx201910003
    [28] Medeiros GS, Rigatto MH, Falci DR, et al. Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection [J]. Int J Antimicrob Agents, 2019, 53:152-157. doi:  10.1016/j.ijantimicag.2018.10.010
    [29] Tumbarello M, Viale P, Viscoli C, et al. Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Impor-tance of Combination Therapy [J]. Clin Infect Dis, 2012, 55:943-950. doi:  10.1093/cid/cis588
    [30] Batirel A, Balkan II, Karabay O, et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections [J]. Eur J Clin Microbiol Infect Dis, 2014, 33:1311-1322. doi:  10.1007/s10096-014-2070-6
    [31] Sirijatuphat R, Thamlikitkul V. Preliminary Study of Colistin versus Colistin plus Fosfomycin for Treatment of Carba-penem-Resistant Acinetobacter baumannii Infections [J]. Antimicrob Agents Ch, 2014, 58: 5598-5601. doi:  10.1128/AAC.02435-13
    [32] Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial [J]. Lancet Infect Dis, 2018, 18: 391-400. doi:  10.1016/S1473-3099(18)30099-9
    [33] Abdellatif S, Trifi A, Daly F, et al. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial [J]. Ann Intensive Care, 2016, 6:26. doi:  10.1186/s13613-016-0127-7
    [34] Valachis A, Samonis G, Kofteridis DP. The Role of Aerosolized Colistin in the Treatment of Ventilator-Associated Pneumonia [J]. Crit Care Med, 2015, 43:527-533. doi:  10.1097/CCM.0000000000000771
    [35] Vardakas KZ, Voulgaris GL, Samonis G, et al. Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis [J]. Int J Antimicrob Agents, 2018, 51:1-9. doi:  10.1016/j.ijantimicag.2017.05.016
    [36] de Bonis P, Lofrese G, Scoppettuolo G, et al. Intraventricular versus intravenous colistin for the treatment of extensively drug resistant Acinetobacter baumannii meningitis [J]. Eur J Neurol, 2016, 23:68-75. doi:  10.1111/ene.12789
    [37] Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence [J]. Int J Antimicrob Agents, 2007, 29:9-25. doi:  10.1016/j.ijantimicag.2006.08.024
    [38] Couet W, Gregoire N, Gobin P, et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers [J]. Clin Pharmacol Ther, 2011, 89:875-879. doi:  10.1038/clpt.2011.48
    [39] Sorlí L, Luque S, Li J, et al. Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical [J]. J Infection, 2019, 79:253-261. doi:  10.1016/j.jinf.2019.06.011
    [40] Liang Q, Huang M, Xu Z. Early use of polymyxin B reduces the mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection [J]. Braz J Infect Dis, 2019, 23:60-65. doi:  10.1016/j.bjid.2018.12.004
    [41] Rigatto MH, Falci DR, Lopes NT, et al. Clinical features and mortality of patients on renal replacement therapy receiving polymyxin B [J]. Int J Antimicrob Agents, 2016, 47:146-150. doi:  10.1016/j.ijantimicag.2015.11.007
    [42] Ismail B, Shafei MN, Harun A, et al. Predictors of polymyxin B treatment failure in Gram-negative healthcare-associated infections among critically ill patients [J]. J Microbiol Immunol, 2018, 51:763-769. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=4c34483f319fad8c58f131002c7903d9
    [43] Dickstein Y, Lellouche J, Ben DAM, et al. Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial [J]. Clin Infect Dis, 2019, 69:769-776. doi:  10.1093/cid/ciy988
    [44] Mattos KPH, Gouvêa IR, Quintanilha JCF, et al. Polymyxin B clinical outcomes: A prospective study of patients undergoing intravenous treatment [J]. J Clin Pharm Ther, 2019, 44:415-419. doi:  10.1111/jcpt.12801
    [45] Maniara BP, Healy LE, Doan T. Risk of Nephrotoxicity Associated With Nonrenally Adjusted Intravenous Polymyxin B Compared to Traditional Dosing [J]. J Pharm Pract, 2020, 33:287-292. doi:  10.1177/0897190018799261
    [46] Sirijatuphat R, Limmahakhun S, Sirivatanauksorn V, et al. Preliminary Clinical Study of the Effect of Ascorbic Acid on Colistin-Associated Nephrotoxicity [J]. Antimicrob Agents Chemother, 2015, 59:3224-3232. doi:  10.1128/AAC.00280-15
    [47] Liu Q, Li W, Feng Y, et al. Efficacy and safety of polymyxins for the treatment of Acinectobacter baumannii infection: a systematic review and meta-analysis [J]. PLoS One, 2014, 9:e98091. doi:  10.1371/journal.pone.0098091
    [48] Pereira GH, Muller PR, Levin AS. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B [J]. Diagn Microbiol Infect Dis, 2007, 58:235-240. doi:  10.1016/j.diagmicrobio.2007.01.008
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(8)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1816) PDF downloads(173) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return